US Government COVID-19 R&D Tracker
The United States has mobilized a whole-of-government effort to support the research and development (R&D) of vaccines, therapeutics, diagnostics, and other technologies to fight COVID-19. Working in close coordination, multiple agencies are contributing their expertise, including the National Institutes of Health (NIH), the Biomedical Advanced Research and Development Authority (BARDA), the Department of Defense (DoD), the Centers for Disease Control and Prevention (CDC), the US Agency for International Development (USAID), and the US Food and Drug Administration (FDA).
The table below captures publicly announced R&D efforts by US agencies and their development status. While GHTC has endeavored to present as much information as accessible, due to the volume of US programming, the number of investments dispersed under umbrella programming, and varying levels of publicly available information, this inevitably includes some gaps and outdated details. However, it still provides an important picture of the US government’s scientific response to this pandemic.
Last updated: February 19, 2021
Click here to access a full version of this table sortable by product type, funding agency, etc.
* Indicates vaccine candidates also supported by the vaccine development partnership the Coalition for Epidemic Preparedness Innovations (CEPI) as part of the Access to COVID-19 Tools Accelerator COVAX Facility, which is a global effort to develop and provide equitable global access to COVID-19 vaccines.
Summary of US agency roles in the COVID-19 response
The coordinated R&D effort for COVID-19 is built on an ecosystem strengthened by decades of US government investment in global health R&D. Within this ecosystem, each US agency is lending unique expertise to the R&D response to COVID-19:
- NIH, largely through the National Institute of Allergy and Infectious Diseases, is a leader in COVID-19 R&D efforts, convening public-private partnerships, coordinating major clinical trial networks, and setting research agendas for basic research and the development of therapeutics, diagnostics, vaccines, and other technologies.
- BARDA, an agency designed to bridge the “valley of death” between basic science and clinical development of new products for which there are limited commercial markets, funds private and nonprofit industry partners to develop vaccines, therapeutics, diagnostics, and other technologies against COVID-19, which BARDA also then procures for the US population.
- DoD conducts and supports research on vaccines, therapeutics, diagnostics, and other technologies; leverages its medical facilities to support clinical trials; and procures products for use by the military.
- CDC, which developed the first diagnostic test for COVID-19 to receive US emergency use approval, coordinates COVID-19 surveillance to understand patterns of transmission, identify and track emerging variants, and inform the research agendas of other agencies based on those insights.
- USAID, building off its decades of experience developing products for use in low-resource settings worldwide, supports development and deployment of select innovations designed to support the global COVID-19 response and provides technical assistance to partner countries.
- FDA provides guidance to product developers, works to rapidly review clinical trial plans to speed R&D efforts, and reviews products for use in the United States via emergency use authorization.